Merck gained Winrevair in its $11.5 billion acquisition of Acceleron in 2021 and got it across the FDA finish line in March of 2024 based on results from the phase 3 STELLAR trial.

Back to Healio The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence ...

The therapy, branded Winrevair, is already approved for treating the rare condition which causes high blood pressure in the lungs, leading to symptoms such as shortness of breath, chest pain and ...

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study RAHWAY, N.J., January 30 ...

This decision suggests that Winrevair has shown significant benefits for patients with pulmonary arterial hypertension, which was initially observed in the STELLAR trial. Graybosch believes that ...

Winrevair generated $200M Get the Real Story Behind Every Major Earnings Report Merck reported adjusted EPS of $1.72, up from $0.03 a year ago and beating the consensus of $1.62. Lower charges for ...

MSD has put a stop to its Phase III HYPERION study investigating its pulmonary arterial hypertension (PAH) treatment Winrevair after the therapy provided positive results from another Phase III trial.

The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of the disease. This decision is based on strong efficacy data from ...

Merck, known as MSD outside of the United States and Canada, announced the phase 3 HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) ...